Does TRICARE Cover Zepbound? Eligibility, Prior Authorization, Copays, and the 2026 Formulary Rules

Key Takeaways

• Yes, TRICARE covers Zepbound for eligible beneficiaries who meet clinical criteria, but coverage requires prior authorization through Express Scripts.
• TRICARE classifies Zepbound as a non-formulary or formulary tier 3 drug depending on the plan year, which means higher copays than tier 1 or tier 2 drugs.
• Eligibility usually requires a BMI of 30 or higher, or a BMI of 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea.
• Active duty service members are subject to additional restrictions because GLP-1 weight-loss medications can affect duty status and deployment readiness.
• If a prior authorization is denied, you can appeal or pay cash through Lilly Direct or pursue compounded tirzepatide through a telehealth platform.

Direct answer (40-60 words)

Yes, TRICARE covers Zepbound for eligible beneficiaries who meet clinical criteria, with prior authorization through Express Scripts. Coverage typically requires a BMI of 30 or higher, or BMI of 27 with a weight-related comorbidity. Zepbound is a non-formulary or tier 3 drug under TRICARE, which means copays of $38 to $76 per 30-day supply for retail pharmacy fills.

Table of contents

1. The 30-second answer
2. Who is eligible for TRICARE Zepbound coverage
3. The prior authorization requirements in detail
4. TRICARE formulary tiers and what they cost
5. Active duty restrictions on GLP-1 weight-loss drugs
6. How to fill Zepbound through TRICARE step-by-step
7. What happens if your prior authorization is denied
8. TRICARE coverage for compounded tirzepatide
9. Cash and savings card options if TRICARE will not cover
10. FAQ
11. Footer disclaimers

Who is eligible for TRICARE Zepbound coverage

TRICARE follows the FDA-approved indication for Zepbound, which is chronic weight management in adults with:

• A body mass index (BMI) of 30 kg/m squared or higher (obesity), OR
• A BMI of 27 kg/m squared or higher (overweight) with at least one weight-related comorbid condition

Qualifying comorbidities recognized by TRICARE include:

• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
• Cardiovascular disease

Beyond the FDA criteria, TRICARE applies its own utilization management rules. Most TRICARE prior authorizations require:

• Documentation of at least 6 months of prior weight-loss attempts through diet, exercise, or behavioral counseling
• A signed treatment plan that includes lifestyle modification alongside medication
• Re-authorization after 6 months that shows at least 5 percent weight loss to continue coverage

The 5 percent weight-loss continuation rule is the rule patients run into most often. If you start Zepbound and lose 3 percent in 6 months, TRICARE may decline to renew authorization (Express Scripts TRICARE formulary 2025).

The prior authorization requirements in detail

TRICARE pharmacy benefits are administered by Express Scripts. Prior authorization for Zepbound is processed through them. The standard PA criteria for 2025 to 2026 require:

1. Patient is age 18 or older
2. BMI documented in the medical record meets thresholds above
3. Failed attempt at lifestyle modification documented for at least 6 months
4. Prescriber attests to ongoing diet and exercise plan
5. Patient does not have personal or family history of medullary thyroid carcinoma or MEN 2 (a contraindication to all GLP-1 medications)
6. No history of pancreatitis (relative contraindication)

Required documentation typically includes:

• Patient height and weight (or calculated BMI) within the last 90 days
• Documented prior weight-loss attempts (Weight Watchers, MOVE program, prior medications, etc.)
• Comorbidity diagnoses with ICD-10 codes if BMI is 27 to 30
• Prescriber's NPI and DEA number

Initial authorizations are typically granted for 6 months. Continuation requires demonstrated weight loss of 5 percent or more from baseline.

TRICARE formulary tiers and what they cost

TRICARE uses a four-tier formulary plus a non-formulary category. As of the 2025 to 2026 plan year, Zepbound falls into either tier 3 (non-preferred brand) or non-formulary depending on the specific TRICARE plan and benefit year.

If Zepbound is on tier 3 in your benefit year, expect a $76 copay for a 30-day retail fill or $76 for a 90-day mail-order fill through Express Scripts Pharmacy. Mail order is the better deal for chronic medications.

Some TRICARE plans (TRICARE for Life, TRICARE Select Overseas, certain Reserve plans) have different cost structures. Check your specific plan's formulary at express-scripts.com/tricare.

Active duty restrictions on GLP-1 weight-loss drugs

Active duty service members face additional restrictions beyond the standard TRICARE rules. Under DoD Instruction 6130.03, weight-loss medications can affect:

• Duty status and fitness for duty determinations
• Deployment eligibility
• Aviation and special-duty assignments (pilot, diver, parachutist, etc.)

GLP-1 medications including Zepbound are generally not approved for use during deployment because of:

• Refrigeration requirements that are difficult to maintain in field conditions
• Risk of hypoglycemia or dehydration in austere environments
• Potential interference with pre-deployment medical readiness

Active duty members who want Zepbound for weight management typically need to:

1. Get medical clearance from their primary care manager (PCM) at the MTF (military treatment facility)
2. Document that weight loss is needed for body composition standards and that diet and exercise alone have not worked
3. Discuss duty status implications with the PCM and command if applicable
4. Plan for discontinuation prior to deployment or special-duty assignment

For most active duty members, MOVE (Managing Overweight and Obesity for Veterans Everywhere) or the equivalent service-specific weight management program is the first-line intervention before medication is considered.

Retirees, dependents, and reservists are not subject to the same duty-related restrictions.

How to fill Zepbound through TRICARE step-by-step

The standard TRICARE workflow for Zepbound:

1. Get a prescription. From your TRICARE PCM, an MTF provider, or a TRICARE-network civilian provider. Telehealth providers in the TRICARE network can also prescribe.

1. Submit the prior authorization. Your prescriber's office submits a PA form to Express Scripts. Forms are at militaryrx.express-scripts.com. Decisions typically come back within 5 to 14 business days.

1. Choose your fill option:

• Mail order through Express Scripts Pharmacy: lowest copay for a 90-day supply, ships to your home, refrigerated packaging
• Retail network pharmacy: higher copay but immediate fill
• MTF pharmacy: $0 copay but Zepbound stocking varies by base; many MTFs do not stock GLP-1 weight-loss drugs

1. Refill on schedule. Zepbound is a once-weekly injection. A 30-day supply is 4 pens at one dose level. Mail order ships 12 pens (90 days) per fill.

1. Re-authorize at 6 months. Bring documented weight loss to your provider for the renewal PA submission.

If you live OAS (overseas), TRICARE Overseas Program covers Zepbound but logistics are more complex. Mail order through Express Scripts Pharmacy ships to APO/FPO addresses.

What happens if your prior authorization is denied

The most common denial reasons for Zepbound under TRICARE are:

• BMI not documented or below threshold
• Comorbidity not adequately documented
• No documentation of prior lifestyle attempts
• Patient under 18 (Zepbound is FDA-approved for adults; teen approval is pending broader rollout)
• Active duty member without MTF coordination

You have appeal rights. The TRICARE appeal process:

1. First-level appeal: Submit additional clinical documentation to Express Scripts within 90 days of the denial. Often resolved within 30 days.

1. Second-level appeal: If the first appeal is denied, you can request a formal reconsideration. This goes to the TRICARE Pharmacy Appeals Office.

1. Final appeal: Independent external review through the Defense Health Agency.

A peer-to-peer call between your prescriber and the Express Scripts pharmacist often resolves borderline cases without a formal appeal.

If all appeals are exhausted and TRICARE will not cover Zepbound, you have three remaining options: pay cash through Lilly Direct, use the Zepbound savings card if you are not on a federal program (Lilly's savings card excludes federal beneficiaries, so this is usually unavailable), or pursue compounded tirzepatide through a telehealth platform.

TRICARE coverage for compounded tirzepatide

TRICARE generally does not cover compounded tirzepatide. Compounded GLP-1 medications are not FDA-approved, and the TRICARE formulary covers FDA-approved drugs with limited exceptions for clinically necessary compounded preparations (typically dermatology, hormone replacement, or pediatric formulations).

If a TRICARE beneficiary chooses to use compounded tirzepatide, it is typically a cash-pay decision through a telehealth platform like FormBlends. Compounded products are prepared by state-licensed compounding pharmacies in response to individual prescriptions. They are not interchangeable with brand-name Zepbound and have not undergone the same review process as FDA-approved drugs.

For active duty members, using cash-pay compounded medications outside the TRICARE benefit may still trigger duty-status considerations because the medication itself can affect deployment readiness. Check with your PCM before starting any GLP-1 medication, including compounded products.

Cash and savings card options if TRICARE will not cover

If TRICARE denies Zepbound and appeals fail, options include:

• Lilly Direct: Lilly's direct-to-patient program offers single-dose vials of Zepbound at $349 for 2.5 mg and $499 for 5 mg per month for cash-pay patients without insurance coverage. Federal beneficiaries are eligible for the cash-pay direct program.
• Zepbound savings card: Lilly's commercial savings card excludes patients with federal pharmacy benefits including TRICARE, Medicare, and Medicaid. Active duty, retirees, and dependents on TRICARE generally cannot use this card.
• GoodRx and other discount cards: Discount cards do not bring Zepbound below cash-pay Lilly Direct pricing, in our review of April 2026 retail pharmacy prices.
• Telehealth platforms with compounded tirzepatide: Cash-pay compounded options through state-licensed pharmacies are an alternative. Pricing typically runs $200 to $400 per month depending on dose and platform.

For most TRICARE beneficiaries who are denied coverage, the calculation comes down to: pay $76 per month with TRICARE coverage, $349 to $499 per month through Lilly Direct, or pursue a compounded option at variable cost.

FAQ

Does TRICARE cover Zepbound? Yes, TRICARE covers Zepbound for eligible beneficiaries who meet BMI and comorbidity criteria, with prior authorization through Express Scripts. Coverage is at the tier 3 or non-formulary copay level depending on plan year.

What BMI is required for TRICARE to cover Zepbound? TRICARE follows the FDA indication: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbid condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

How much does Zepbound cost with TRICARE? At the tier 3 retail copay, $76 for a 30-day supply. Mail order through Express Scripts Pharmacy is also $76 for a 90-day supply, which is the better value. Active duty members with $0 copay at MTF pharmacy may pay nothing if the MTF stocks Zepbound.

Can active duty get Zepbound through TRICARE? Yes, but with additional restrictions. Active duty members need PCM clearance and need to consider deployment and special-duty implications. GLP-1 medications are generally not approved for use during deployment.

Does TRICARE require prior authorization for Zepbound? Yes. Prior authorization is required and is processed through Express Scripts. Documentation includes BMI, comorbidities if applicable, prior weight-loss attempts, and a treatment plan that includes lifestyle modification.

How long does TRICARE prior authorization take for Zepbound? Standard PA decisions come back within 5 to 14 business days. Appeals can take an additional 30 to 60 days at each level.

Does TRICARE cover compounded tirzepatide? Generally no. TRICARE covers FDA-approved drugs and does not typically cover compounded GLP-1 medications. Beneficiaries who want compounded tirzepatide usually pay cash through a telehealth platform.

What if TRICARE denies my Zepbound prior authorization? You have appeal rights. Submit additional clinical documentation through your prescriber. A peer-to-peer call between your prescriber and the Express Scripts pharmacist often resolves borderline cases. If all appeals fail, Lilly Direct cash-pay is the most common alternative.

Can I use the Zepbound savings card with TRICARE? No. Lilly's commercial savings card excludes patients with federal pharmacy benefits including TRICARE. Federal beneficiaries can use Lilly Direct cash-pay pricing instead.

Does TRICARE cover Zepbound for teens? Zepbound is FDA-approved for adults aged 18 and older. Teen approval and pediatric coverage are pending broader rollout. Check with your TRICARE PCM and Express Scripts for the current age threshold under your plan year.

Will TRICARE cover Zepbound if I switch from Wegovy or Mounjaro? Generally yes, with a fresh prior authorization showing the clinical reason for the switch. Examples include intolerance, supply shortage, or inadequate response to the prior medication.

Does TRICARE for Life cover Zepbound for retirees on Medicare? TRICARE for Life is a wraparound benefit for Medicare-eligible retirees. Medicare Part D plans determine primary coverage of self-administered drugs, with TRICARE for Life paying secondary. Coverage depends on the specific Part D plan's formulary. Most Medicare Part D plans do not cover GLP-1 medications for weight loss alone, but covering for diabetes (Mounjaro) is more common.

Sources

1. Express Scripts. TRICARE Formulary Search Tool. militaryrx.express-scripts.com. Accessed April 2026.
2. Defense Health Agency. TRICARE Pharmacy Program Handbook. 2025 edition.
3. Department of Defense. DoD Instruction 6130.03, Volume 2: Medical Standards for Military Service. 2024 revision.
4. Eli Lilly. Zepbound (tirzepatide) prescribing information. Indianapolis, IN; 2024.
5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
6. Centers for Medicare and Medicaid Services. Medicare Part D drug coverage of weight-loss medications. Final rule guidance, 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk. TRICARE is a registered trademark of the U.S. Department of Defense. Express Scripts is a trademark of Express Scripts Holding Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or agencies.